Trident Texofab Ltd — Others, 04-06-2025: Corp Action

Trident Texofab Limited has announced a board meeting outcome approving the conversion of 4,81,907 warrants into an equal number of equity shares at an issue price of Rs. 70 each (including a Rs. 60 premium). The company has received Rs. 2.53 Cr as the balance payment for conversion from non-promoter investors. This increases the issued and paid-up capital to Rs. 14.99 Cr with 1.49 crore equity shares outstanding. A total of 9,11,479 warrants remain convertible within 18 months. This equity dilution raises capital and broadens the shareholder base, supporting future growth.